title: Feline extranodal lymphoma: response to chemotherapy and survival in 110 cats.
abstract: OBJECTIVE
  To determine response to treatment, survival and prognostic factors for feline extranodal lymphoma in the UK.
  
  
  METHODS
  Records of cats diagnosed with lymphoma of extranodal sites at seven referral centres were reviewed and information on signalment, tumour location, prior treatment and chemotherapy protocol recorded. Factors influencing response to treatment and survival were assessed.
  
  
  RESULTS
  One hundred and forty-nine cases met inclusion criteria. Sixty-nine cats had nasal lymphoma, 35 renal, 15 central nervous system, 11 laryngeal and 19 miscellaneous locations. Sixty-six cats received cyclophosphamide, vincristine, prednisolone, 25 Wisconsin-Madison doxorubicin-containing multi-agent protocol, 10 prednisolone alone and nine other combinations. The response rate for the 110 treated cats was 85.5 per cent. Of cyclophosphamide, vincristine, prednisolone treated cats 72.7 per cent achieved complete remission, median survival 239 days. Sixty-four per cent of Wisconsin-Madison treated cats achieved complete remission, median survival 563 days. Cats with nasal lymphoma achieving complete remission had the longest survival (749 days) and cats with central nervous system lymphoma the shortest (70 days). If complete remission was achieved, prior treatment with corticosteroids significantly reduced survival time.
  
  
  CONCLUSIONS
  Cats with extranodal lymphoma respond to chemotherapy and achieve survival times comparable to other locations. Corticosteroid pretreatment reduced survival time in cats achieving complete remission.
authors.affiliation: The Feline Centre, Department of Clinical Veterinary Science, Division of Companion Animals, University of Bristol, Langford, Bristol BS405DU.
authors.forename: S S
authors.initials: SS
authors.lastname: Taylor
authors.forename: M R
authors.initials: MR
authors.lastname: Goodfellow
authors.forename: W J
authors.initials: WJ
authors.lastname: Browne
authors.forename: B
authors.initials: B
authors.lastname: Walding
authors.forename: S
authors.initials: S
authors.lastname: Murphy
authors.forename: S
authors.initials: S
authors.lastname: Tzannes
authors.forename: M
authors.initials: M
authors.lastname: Gerou-Ferriani
authors.forename: A
authors.initials: A
authors.lastname: Schwartz
authors.forename: J M
authors.initials: JM
authors.lastname: Dobson
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000401:mortality*; D002415:Cats; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D005260:Female; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D009669:Nose Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D006113:United Kingdom